腫瘍微小環境における免疫療法モジュレーターをプロファイリングするプラットフォームを開発(Researchers Develop Platform for Profiling Immunotherapy Modulators Within Tumor Microenvironment)

ad

2026-02-13 中国科学院(CAS)

中国科学院分子細胞科学卓越創新センター(上海生化学・細胞生物学研究所)のWANG Guangchuan教授らは、腫瘍内在性遺伝子変異と転移巣の免疫微小環境、免疫療法応答を因果的に結び付ける高スループット空間スクリーニング基盤「CLIM-TIME」を開発し、Cell誌に発表した。CRISPR遺伝子改変とレーザー捕捉マイクロダイセクションを統合し、391種の腫瘍抑制遺伝子欠損が誘導する肺転移巣を解析。微小環境を7類型に分類し、T細胞排除型や免疫砂漠型が治療抵抗性と関連することを示した。特にHippo経路異常やLOXL2高発現がコラーゲン沈着と骨髄系細胞浸潤を促進しT細胞浸潤を阻害。LOXL2阻害によりTCR-TやCAR-T療法効果が向上することを実証した。

<関連情報>

CLIM-TIMEがT細胞療法への反応における転移性微小環境調節因子を特定 CLIM-TIME identifies metastatic microenvironment modulators for T cell therapy response

Yinghua Wang, ∙ Weiwei Hu ∙ Rui Xia ∙ … ∙ Naihe Jing ∙ Luonan Chen ∙ Guangchuan Wang
Cell  Published:February 11, 2026
DOI:https://doi.org/10.1016/j.cell.2025.12.042

Graphical abstract

腫瘍微小環境における免疫療法モジュレーターをプロファイリングするプラットフォームを開発(Researchers Develop Platform for Profiling Immunotherapy Modulators Within Tumor Microenvironment)

Highlights

  • CLIM-TIME spatially maps the tumor microenvironment after tumor suppressor gene loss
  • Seven metastatic TME subtypes are defined and associated with immune states
  • Hippo-YAP loss shapes myeloid-rich T cell-excluded niches high in extracellular matrix
  • LOXL2 inhibition remodels metastases, improving T cell infiltration and immunotherapy

Summary

The tumor microenvironment (TME) poses a major barrier to effective immunotherapy, yet high-throughput perturbation-mapping approaches to dissect TME spatial complexity and its contextual immune modulators remain lacking. Here, we introduce CRISPR-laser-captured microdissection (LCM) integration mapping of the tumor-immune microenvironment (CLIM-TIME), a scalable platform that integrates CRISPR screening with LCM of metastatic tumors for transcriptomic, deconvolution, and immunofluorescence analyses. CLIM-TIME enables spatially resolved mapping of how tumor suppressor gene (TSG) loss reshapes the TME and modulates immune responses. We identified seven distinct TME subtypes, revealing that DNA repair and Polycomb repressive complex (PRC) TSG loss is linked to immune-infiltrated TMEs sensitive to T cell therapy. In contrast, knockouts of TSGs in the Hippo pathway promoted immune evasion and therapy resistance by fostering myeloid-enriched but T cell-excluded TMEs with elevated extracellular matrix (ECM). Targeting the ECM-crosslinking enzyme LOXL2 effectively remodeled the metastatic TME, enhancing T cell infiltration and improving therapeutic efficacy in lung metastases across multiple cancers.

細胞遺伝子工学
ad
ad
Follow
ad
タイトルとURLをコピーしました